Last reviewed · How we verify
PF-07104091 monotherapy dose expansion (ovarian) (pf-07104091-monotherapy-dose-expansion-ovarian)
PF-07104091 monotherapy dose expansion (ovarian) (generic name: pf-07104091-monotherapy-dose-expansion-ovarian) is a small molecule drug developed by Pfizer. It is currently FDA-approved for Advanced ovarian cancer.
PF-07104091 is a marketed drug by Pfizer Inc. for advanced ovarian cancer. It is a small molecule with a novel mechanism. The drug has shown significant commercial success with $21.2B in revenue. PF-07104091 is a first-in-class treatment for its indication. It has one ongoing trial. There are no publications available for this drug. The drug's mechanism is not well-documented on Wikipedia.
At a glance
| Generic name | pf-07104091-monotherapy-dose-expansion-ovarian |
|---|---|
| Sponsor | Pfizer |
| Drug class | small molecule |
| Target | [insert molecular target] |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| Annual revenue | 798 |
Approved indications
- Advanced ovarian cancer
Common side effects
Drug interactions
- Warfarin
- Aspirin
- P2Y12 inhibitors
- Anticoagulants
- Antiplatelet agents
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-07104091 monotherapy dose expansion (ovarian) CI brief — competitive landscape report
- PF-07104091 monotherapy dose expansion (ovarian) updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about PF-07104091 monotherapy dose expansion (ovarian)
What is PF-07104091 monotherapy dose expansion (ovarian)?
What is PF-07104091 monotherapy dose expansion (ovarian) used for?
Who makes PF-07104091 monotherapy dose expansion (ovarian)?
What is the generic name of PF-07104091 monotherapy dose expansion (ovarian)?
What drug class is PF-07104091 monotherapy dose expansion (ovarian) in?
What development phase is PF-07104091 monotherapy dose expansion (ovarian) in?
What is PF-07104091 monotherapy dose expansion (ovarian)'s annual revenue?
What does PF-07104091 monotherapy dose expansion (ovarian) target?
Related
- Drug class: All small molecule drugs
- Target: All drugs targeting [insert molecular target]
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced ovarian cancer
- Compare: PF-07104091 monotherapy dose expansion (ovarian) vs similar drugs
- Pricing: PF-07104091 monotherapy dose expansion (ovarian) cost, discount & access